NEONATAL RESPIRATORY TRIALS IN SICK & PRETERM NEWBORN INFANTS
Professor Brett J. Manley, Consultant Neonatologist
Mercy Hospital For Women, Melbourne & Professor of Neonatal Medicine, Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2025
Professor Brett J. Manley is a Consultant Neonatologist at the Mercy Hospital for Women in Melbourne, Australia, and a Professor of Neonatology in the Department of Obstetrics, Gynaecology and Newborn Health at The University of Melbourne. His research is supported by a fellowship from the National Health and Medical Research Council (NHMRC), Australia.
He divides his work time between being a clinician in the neonatal intensive care unit (NICU), and a clinical researcher. He is passionate about caring for sick and preterm newborn infants and contributing to the evidence base for their care, to improve their shorter- and longer-term outcomes.
Prof Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
Source: Supplied
https://orcid.org/0000-0003-0212-7956
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
